<DOC>
	<DOCNO>NCT00555438</DOCNO>
	<brief_summary>Fondaparinux antithrombotic agent already receive regulatory approval European Authorities venous thromboembolic event prevention major orthopaedic surgery , total hip replacement ( THR ) , total knee replacement ( TKR ) , hip fracture ( HF ) . The bleeding risk associate prescription highly related renal function evaluate creatinin clearance ( CrCl ) . In order reduce bleed risk , propose prescribe fondaparinux 1.5 mg/day patient CrCl 20 50ml/mn instead 2.5mg/day ( European MMA ) . In meantime , approval essentially base simulate pharmakinetic data without support clinical data . prospective , multicentre , open-label study evaluate safety profile fondaparinux 1.5 mg/day , subcutaneously administer , patient renal impairment define CrCl 20 30 ml/min undergo major orthopaedic surgery .</brief_summary>
	<brief_title>Prospective , Multicentre , Open-label Study Evaluating 1.5 mg/Day Fondaparinux .</brief_title>
	<detailed_description>Fondaparinux 1.5mg/day subcutaneously administer post-surgery 1 10 day 1st treatment administration perform 6 8 hour end surgery . Screening visit : &gt; 7 day inclusion visit THR TKR Inclusion visit : day surgery Visits blood drawing : 3 visit schedule 1 10 day treatment period Study end treatment visit : D1 D10 Study end visit : 1 month ± 15 day</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>• age &gt; 18 year old , undergoing major orthopaedic surgery ( THR , TKR , HF ) whatever procedure technique use , 1st indication 2nd indication , require antithrombotic prophylaxis , present renal impairment define creatinin clearance ( CrCl ) 20 50 ml/min calculate Cockcroft Gault 's formula , sign inform consent form . contraindication fondaparinux , history heparin induct thrombopenia ( HIT ) , platelets &lt; 100 g/l .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>major orthopaedic surgery</keyword>
	<keyword>venous thromboembolic event prevention</keyword>
	<keyword>renal impairment</keyword>
	<keyword>Arixtra</keyword>
	<keyword>anti-Xa activity</keyword>
</DOC>